Business Wire

Elliott Advisors (UK) Limited Statement on Telecom Italia

Del

Elliott Advisors (UK) Limited (“Elliott”) has had the opportunity in recent weeks to engage constructively with many of Telecom Italia’s (“TIM”, or the “Company”) key stakeholders, including the CEO Mr. Amos Genish, members of the management team, other shareholders and many other market participants.

Fundamentally, Elliott believes that Telecom Italia is uniquely positioned in the Italian market and operates an outstanding collection of assets with the potential to produce substantial, consistent returns for its shareholders while enhancing a nationally strategic infrastructure asset. However, poor stewardship under the Vivendi-controlled Board has resulted in deeply troubling corporate governance issues and a pervasive and persistent valuation discount. At this juncture, Elliott believes an independent Board of Directors is paramount to resolving these issues and to maximising value creation for all stakeholders.

With respect to certain value realisation opportunities put forward by Elliott on April 9th, Elliott believes that the management team led by Mr. Genish, together with an independent Board should evaluate whether and when to carry out strategic initiatives, in the best interest of value creation for all shareholders.

Regarding Netco, Elliott notes Mr. Genish’s statements on the possibility of selling a minority stake while retaining control:“…I have said to investors [that] we are ready to open a minority part of the capital and list the network provided that the future regulatory status is secure.” 1 Elliott trusts the management and an independent Board’s ability to evaluate these initiatives in the interest of maximizing shareholder value.

Further, with respect to the dividend, given the prospect of TIM achieving investment grade in 2018, Elliott accepts the importance of achieving this target before committing to pay a dividend.

In short, Elliott has sought to offer constructive ideas to enhance TIM’s value creation plan as presented by Mr. Genish on March 7th. There is no alternative business plan. Elliott and its proposed independent nominees fully support Mr. Genish and are encouraged that Mr. Genish has committed to remain at TIM to execute his plan with the full support of the Board of the Directors, regardless of its composition:

  • April 19th: “Elliott believes management should be led by the current CEO and the board of directors rather than by a single shareholder.” 2
  • April 24th: “We are very confident in the current management team led by the CEO Amos Genish.” 3
  • April 26th: We fully support TIM’s CEO, Mr. Amos Genish…We also support the business plan that Mr. Genish and his management team have put forward.” 4

Elliott seeks to ensure Mr. Genish and his entire management team are equipped to maximise the value creation attributable to TIM’s business plan by aligning TIM with international corporate governance best practices and equipping the Company with a qualified independent Board. To that end, Elliott has proposed a slate of ten independent, highly qualified, credible nominees that share Mr. Genish’s vision for TIM’s future and are fully supportive of TIM’s business plan.

To reiterate, if elected, the independent nominees would evaluate the merits of Elliott’s value creation proposals as described above in conjunction with management, to determine whether and when to implement them in the best interest of long-term value creation for all shareholders. Elliott is just a shareholder; TIM’s Board and management team will have the responsibility to address the optimal timing and strategy for the Company.

Elliott trusts shareholders will join it in setting the right conditions and appointing the right team at the Board level by voting for Elliott’s proposed slate on May 4th to allow TIM’s many stakeholders to thrive in the years ahead. With proper stewardship at the Board level, and a highly qualified independent Board of Directors, Elliott believes TIM’s prospects are bright.

Full materials and today’s presentation can be found at our dedicated website www.transformingtim.com.

About Elliott

Elliott Management Corporation manages two multi-strategy funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.

1 Interview with Mr. Genish in Les Echos, April 4th, https://www.lesechos.fr/tech-medias/hightech/0301514255731-amos-genish-vivendi-a-une-vision-long-terme-pour-telecom-italia-contrairement-a-elliott-2166165.php

2 Elliott statement, April 19th, https://www.transformingtim.com/media/1052/elliott-advisors-uk-limited-response-to-vivendi-statements.pdf

3 TIM AGM, April 24th, in conjunction with a vote in support of Mr. Genish as CEO

4 Elliott letter to shareholders, April 26th, https://www.transformingtim.com/media/1061/elliott_tim_letter_260418.pdf

Contact information

Media
London
Elliott Advisors (UK) Limited
Sarah Rajani CFA, +44 (0) 20 3009 1475
srajani@elliottadvisors.co.uk
or
Milan
Verini & Associates
Marcella Verini, +39 (02) 4539 5500
mverini@verinieassociati.com
or
Paris
Steele & Holt
Daphne Claude / Dominic Riding
+33 (0) 6 66 58 81 92 / +33 (0) 6 48 57 83 24
daphne@steeleandholt.com / dominic@steeleandholt.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective Treatment for COPD20.5.2018 21:15Pressemelding

ResMed (NYSE: RMD, ASX: RMD) announced today the results of two clinical analyses conducted for the U.K. and U.S., demonstrating the cost effectiveness of combining home oxygen therapy and home non-invasive ventilation (NIV) therapy for patients with persistent hypercapnia following a life-threatening exacerbation of chronic obstructive pulmonary disease (COPD). The ResMed-backed Home Oxygen Therapy – Home Mechanical Ventilation (HOT-HMV) health economic studies, presented today at the ATS 2018 International Conference, build on earlier data demonstrating the clinical and cost effectiveness of HOT-HMV therapy (i.e. combining home oxygen therapy with home NIV), compared to treating with oxygen alone. The U.K. study found that HOT-HMV treatment reduced exacerbation frequency and 28-day hospital readmission. The U.S. analysis found a 58.3 percent reduction in 30-day readmissions for HOT-HMV patients compared to those on home oxygen alone – and that HOT-HMV can actually save patients money

WELL Building Standard Gaining Momentum in Europe18.5.2018 14:47Pressemelding

As Greenbuild Europe came to a close in Berlin, the International WELL Building Institute™ (IWBI™) used the occasion to highlight how the WELL Building Standard™ (WELL™) has elevated health and well-being to the forefront of sustainability conversations across Europe. WELL continues to advance the healthy building movement as the premier standard for buildings, interior spaces and communities seeking to implement, validate and measure features that promote human health and wellness. The resonance of the program has spurred innovations across the building, design and construction industries, providing projects with customizable approaches to address geographical and cultural health concerns. To date, WELL has enrolled more than 830 projects encompassing over 155 million square feet of real estate in 32 countries worldwide. In Europe nearly 190 projects across 13 countries are engaged with WELL, representing 25% of global WELL project square footage. The strong growth of WELL over the pa

Utimaco Announces Intent to Acquire Atalla from Micro Focus18.5.2018 09:03Pressemelding

Utimaco, the global #2 in Hardware Security Modules (HSMs), today announced the intent to acquire the Atalla HSM and ESKM business lines from Micro Focus, which were previously owned by Hewlett Packard Enterprise (HPE) prior to the September 2017 merger of its Software business with Micro Focus. Germany-based Utimaco, active in the HSM market for over 35 years, is a global manufacturer of general purpose HSMs. Utimaco has built its market leading position focusing on indirect sales through OEM or channel business partners and selling its SecurityServer product line into industries as diverse as automotive, government, media & entertainment, smart metering, semiconductors, telecommunications and the banking and financial services sectors. Utimaco is traditionally strong in its German home market based on its longstanding German banking association certification (DK) and has recently achieved PCI accreditation for the SecurityServer product line. With the acquisition of Atalla, one of th

Janssen to Present New Data in Urothelial, Haematologic and Prostate Cancers at ASCO 2018, including Best of ASCO Selections18.5.2018 07:00Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson, today announced 21 company-sponsored abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1-5. New data analyses in support of a portfolio of products, including the investigational treatments erdafitinib and apalutamide, as well as approved treatments Imbruvica® (ibrutinib), Darzalex® (daratumumab), and Zytiga® (abiraterone acetate) will be highlighted across urothelial, haematologic and prostate cancers. Notably, Phase 2 trial results for the investigational compound erdafitinib, which received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation, will be presented during an oral presentation on Sunday, June 3 (Abstract #4503).1,2 For haematologic cancers, Phase 3 data from the iNNOVATE study will provide the first look at ibrutinib plus rituximab versus placebo plus rituximab in patients with newly diagnosed and relapsed/refractory Wald

Karisma Hotels & Resorts to Open Allure Palazzi Kotor Bay Hotel by Karisma in June 201818.5.2018 06:00Pressemelding

Karisma Hotels & Resorts, an award-winning luxury hotel collection which owns and manages properties in Latin America, the Caribbean and Europe, is pleased to announce the opening of Allure Palazzi Kotor Bay Hotel by Karisma in June 2018. Built from the ground up in Montenegro’s idyllic Dobrota, the exclusive five-star beachfront property seamlessly blends stunning architecture and design with its mountainous landscape, offering spellbinding views of Kotor Bay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180517006456/en/ Rendering of Allure Palazzi Kotor Bay (Photo: Business Wire) Sitting on Kotor Bay’s only private beach, the resort features 89 premium guestrooms, 10 villas with private beachfront access, and three breathtaking penthouse suites, each with a balcony or terrace. Allure Palazzi Kotor Bay’s accommodations encompass sumptuous bedding, divine amenities, and carefully selected color palettes bringing the sunny

Siemens Financial Services Selects GTC’s @GlobalTrade Platform for Management of Export Documentary Credits18.5.2018 04:00Pressemelding

GlobalTrade Corporation (GTC) has announced today that Siemens Financial Services (SFS) has selected its @GlobalTrade Multi-bank Trade Finance Platform for management of its export documentary credits. The platform will be initially rolled out in Germany and thereafter expanded to Siemens entities globally. The system will electronically aggregate all incoming documentary credits in a global database, facilitate review and approval, assist in preparation of compliant documents and enable faster presentation of documents electronically to advising and issuing banks. Gerhard Heubeck, Head of Trade Finance Advisory at Siemens Financial Services, reasons the need for the new system implementation as follows: "After many years of using one of the first standard IT systems available for export documentary credits, the time has come to find a successor tool capable to meet the new requirements such as multi-client capability, processing of new SWIFT message formats, global accessibility, and